July 20, 2017
Written by AVAC
This article originally appeared on AVAC. Reposted with permission.
This post contains information on the upcoming IAS 2017 conference taking place July 23–26 in Paris. Read on for details on AVAC satellite sessions, data to watch for, a prevention roadmap and all the ways to follow next week’s developments from the City of Light!
Held every two years, this year’s conference will include results from several HIV prevention trials, including data from HPTN’s Phase II long-acting injectable PrEP trial as well as Janssen’s Phase II vaccine trial, important findings from PrEP clinical trials, initial evidence of impact on confronting the epidemic in Swaziland, and more!
The full conference schedule is available on the conference website, and AVAC has pulled together an HIV prevention roadmap, sortable by timing, intervention and session type (also available as a PDF). The conference organizers have also engaged with partners to create additional roadmaps, which can be viewed here.
We also hope that you’ll mark your calendars for two Sunday satellite sessions that AVAC and partners are organizing:
The Next Wave of Prevention Options: An update and interactive discussion on the pipeline of injections, infusions and implants—who will use, who will deliver, who will pay
Sunday 23 July, 14:45 – 16:45, Maillot Room
Join advocates, researchers and implementers, including Ambassador Deborah Birx, in a discussion on HIV prevention R&D, what potential users want from this next wave of prevention options, what’s scientifically feasible, what trials might look like, the development pathways and how to work together to accelerate progress.
Future Perfect: Opportunities and Obstacles for HIV Vaccines
Sunday 23 July, 17:00 – 19:00, Maillot Room
This satellite will feature three state-of-the-art presentations on the vaccine pipeline, including passive immunization, promising vector-platforms, and the development of envelope proteins able to elicit broadly neutralizing antibodies. The presentations will be followed by a moderated discussion on the scientific priorities, challenges, and opportunities for next-generation vaccines.
Following on the Web
Stay tuned for additional updates, and we welcome questions and comments at firstname.lastname@example.org!